NCT00154544|Unknown
Searching for the Liver Cancer-Related Biomarkers
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX
Loading search results
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by PROTEOMEX
Sponsor study identifier
Secondary identifiers
observational
50
1 country
1
Study Start
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedHepatocellular carcinoma (HCC) has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. Though regular sonographic examination can early detect small HCC and there are many therapeutic modalities for HCC, the therapeutic results remains unsatisfactory. Though Alpha-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) are used as the tumor markers for diagnosis of HCCs, these two markers are not good enough for the early detection of small HCCs. To improve the survival, further investigations of the early diagnostic markers are still needed. In this current project, we applied the proteomic method to identify the HCC biomarkers.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
September 9, 2005
Actual (reported)September 12, 2005
Actual (reported)Contact the study team to confirm eligibility.
National Taiwan University Hospital
Taipei, 100, Taiwan
Chien-Hung Chen, MD
National Taiwan University Hospital
First Submitted
September 9, 2005
First Posted
September 12, 2005
Study Start
August 2004
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
December 20, 2005
Record last verified: 2003-12
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: